Monthly Archives: July 2016

What is Osteoarthritis? Osteoarthritis (OA) is a degenerative joint disorder. It is a common type of arthritis where nearly 15 million patients are affected by this condition every year in India. The main reason for OA is wear and tear of the articular cartilage and ligament, loss of synovial fluid or loss of regenerative capacity of chondrocytes. The articular cartilage is especially vulnerable to damage. Normal load-bearing capacity and biomechanical properties of thinning cartilage are severely compromised during the course of disease progression. Common joints that are affected by Osteoarthritis are Knee, Hip, Hand Joints, Neck etc. What Causes Osteoarthritis? Osteoarthritis symptoms and signs Osteoarthritis is a progressive joint disease, The most common symptoms of osteoarthritis are: Common symptoms related to the following conditions possibly treated by mesenchymal stem cells for osteoarthritis as well as bone-related injuries: Osteoarthritis is characterized by joint pain, stiffness, inflammation and reduced movement of the joints. OA being a degenerative disease and with pain making day to day activities more difficult, It is crucial to find a way to cope with the pain and the discomfort. There are several exercises for osteoarthritis of the knee. Although surgical and pharmaceutical interventions are currently available for treating … Continue reading →

Abstract Cell transplantation has been well explored for cartilage regeneration. We recently showed that the entire articular surface of a synovial joint can regenerate by endogenous cell homing and without cell transplantation. However, the sources of endogenous cells that regenerate articular cartilage remain elusive. Here, we studied whether cytokines not only chemotactically recruit adipose stem cells (ASCs), mesenchymal stem cells (MSCs), and synovium stem cells (SSCs) but also induce chondrogenesis of the recruited cells. Recombinant human transforming growth factor-3 (TGF-3; 100 ng) and/or recombinant human stromal derived factor-1 (SDF-1; 100 ng) was control released into an acellular collagen sponge cube with underlying ASCs, MSCs, or SSCs in monolayer culture. Although all cell types randomly migrated into the acellular collagen sponge cube, TGF-3 and/or SDF-1 recruited significantly more cells than the cytokine-free control group. In 6 wk, TGF-3 alone recruited substantial numbers of ASCs (55865) and MSCs (30252), whereas codelivery of TGF-3 and SDF-1 was particularly chemotactic to SSCs (400120). Proliferation of the recruited cells accounted for some, but far from all, of the observed cellularity. TGF-3 and SDF-1 codelivery induced significantly higher aggrecan gene expression than the cytokine-free group for ASCs, MSCs, and SSCs. Type II collagen gene expression was … Continue reading →

Verified March 2015 by Hospital de Cruces Sponsor: Collaborators: Hospital Universitario Getafe Hospital Infantil Universitario Nio Jess, Madrid, Spain Information provided by (Responsible Party): Clara I. Rodrguez, Hospital de Cruces ClinicalTrials.gov Identifier: NCT02172885 First received: June 12, 2014 Last updated: March 17, 2015 Last verified: March 2015 The purpose of this study is to determine the safety and effectiveness of two infusions of characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta (OI). Two Mesenchymal Stem Cell infusions Mesenchymal Stem Cell Infusions The principal aim of this trial is to assess the safety of non-mutated HLA-identical Mesenchymal stem cell (MSC) transplantation for OI pediatric patients irrespective of treatment with biphosphonates. Since MSC are inherently non-immunogenic and do not elicit proliferation of allogeneic lymphocytes (in co-culture experiments), a cell therapy based on HLA-identical or histocompatible (at least 5 shared out of 6 HLA antigens) allogenic MSC may be accomplished without subjecting the patients to immunosuppressor treatment. Adverse secondary effects due to immunosuppressor treatment will be avoided using this strategy thus patients may benefit from two cellular infusions. The patients will be followed for 3 and a half years post their second and last MSC infusion. Inclusion Criteria: Exclusion Criteria: Please … Continue reading →

Prolonged life expectancy, life style and environmental changes have caused a changing disease pattern in developed countries towards an increase of degenerative and autoimmune diseases. Stem cells have become a promising tool for their treatment by promoting tissue repair and protection from immune-attack associated damage. Patient-derived autologous stem cells present a safe option for this treatment since these will not induce immune rejection and thus multiple treatments are possible without any risk for allogenic sensitization, which may arise from allogenic stem cell transplantations. Here we report the outcome of treatments with culture expanded human adipose-derived mesenchymal stem cells (hAdMSCs) of 10 patients with autoimmune associated tissue damage and exhausted therapeutic options, including autoimmune hearing loss, multiple sclerosis, polymyotitis, atopic dermatitis and rheumatoid arthritis. For treatment, we developed a standardized culture-expansion protocol for hAdMSCs from minimal amounts of fat tissue, providing sufficient number of cells for repetitive injections. High expansion efficiencies were routinely achieved from autoimmune patients and from elderly donors without measurable loss in safety profile, genetic stability, vitality and differentiation potency, migration and homing characteristics. Although the conclusions that can be drawn from the compassionate use treatments in terms of therapeutic efficacy are only preliminary, the data provide convincing … Continue reading →